九十岁以上与百岁老人中的神经病理负荷与痴呆:两个社区队列的比较
本研究比较两个社区队列(90+研究与ACT研究)中90岁及以上受试者的神经病理负荷与痴呆关联,发现各病理变量与痴呆的独立关联在三组间相似,但微血管脑损伤仅在ACT<90组与痴呆风险增加相关(OR 1.5,95%CI 1.2-1.8,p<0.001);加权PAF提示不同人群可能需要不同的痴呆干预措施。
要点
- 90+研究参与者比ACT<90和ACT90+组有更高的淀粉样蛋白/ tau负荷。
- ACT90+队列的LATE-NC、微血管脑损伤和总神经病理负荷显著更高。
- 微血管脑损伤仅在ACT<90组与痴呆风险增加相关(OR 1.5,95%CI 1.2-1.8,p<0.001)。
核心结论
- 特定神经病理特征对痴呆的影响在来自不同选择标准和研究设计的九十岁以上与百岁老人队列中可能不同。
- 微血管病变似乎对较年轻参与者的痴呆影响比更年长参与者更显著。
- 不同人群可能需要不同的痴呆干预措施,强调需要疾病特异性生物标志物。
研究设计与样本
- 比较两个大型社区队列(90+研究和成人思维变化研究ACT)的临床病理队列,纳入90岁及以上参与者。
- 对尸检参与者评估痴呆相关神经病理变化,使用逻辑回归或线性回归分析关联,并估计每种神经病理变化的加权人群归因分数(PAF)。
主要发现
- 90+研究参与者(n=414)死亡时平均年龄97.7岁,淀粉样蛋白/tau负荷高于ACT<90组(n=418,平均死亡年龄83.5岁)和ACT90+组(n=401,平均死亡年龄94.2岁)。
- ACT90+队列的LATE-NC、微血管脑损伤(μVBI)和总神经病理负荷显著更高。
- 个体神经病理病变与痴呆几率的独立关联在三组间相似,但μVBI例外,仅在ACT<90组与痴呆风险增加相关(OR 1.5,95%CI 1.2-1.8,p<0.001)。
- 加权PAF提示消除μVBI虽在ACT90+参与者中更普遍,但对痴呆影响很小;相反,在ACT<90中消除μVBI理论上可降低痴呆,加权PAF=6.1%,95%CI 3.8-8.4,p=0.001,与AD神经病理变化的速率相似。
- 在90+研究中减少LATE-NC可能更大程度降低痴呆(加权PAF=5.1%,95%CI 3.0-7.3,p=0.001),高于任一ACT队列(加权PAF=1.69,95%CI 0.4-2.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The aim of this study was to compare 2 large clinicopathologic cohorts of participants aged 90+ and to determine whether the association between neuropathologic burden and dementia in these older groups differs substantially from those seen in younger-old adults. METHODS: Autopsied participants from The 90+ Study and Adult Changes in Thought (ACT) Study community-based cohort studies were evaluated for dementia-associated neuropathologic changes. Associations between neuropathologic variables and dementia were assessed using logistic or linear regression, and the weighted population attributable fraction (PAF) per type of neuropathologic change was estimated. RESULTS: The 90+ Study participants (n = 414) were older (mean age at death = 97.7 years) and had higher amyloid/tau burden than ACT <90 (n = 418) (mean age at death = 83.5 years) and ACT 90+ (n = 401) (mean age at death = 94.2 years) participants. The ACT 90+ cohort had significantly higher rates of limbic-predominant age-related TDP-43 encephalopathy (LATE-NC), microvascular brain injury (μVBI), and total neuropathologic burden. Independent associations between individual neuropathologic lesions and odds of dementia were similar between all 3 groups, with the exception of μVBI, which was associated with increased dementia risk in the ACT <90 group only (odds ratio 1.5, 95% CI 1.2-1.8, p < 0.001). Weighted PAF scores indicated that eliminating μVBI, although more prevalent in ACT 90+ participants, would have little effect on dementia. Conversely, eliminating μVBI in ACT <90 could theoretically reduce dementia at a similar rate to that of AD neuropathologic change (weighted PAF = 6.1%, 95% CI 3.8-8.4, p = 0.001). Furthermore, reducing LATE-NC in The 90+ Study could potentially reduce dementia to a greater degree (weighted PAF = 5.1%, 95% CI 3.0-7.3, p = 0.001) than either ACT cohort (weighted PAFs = 1.69, 95% CI 0.4-2.7). DISCUSSION: Our results suggest that specific neuropathologic features may differ in their effect on dementia among nonagenarians and centenarians from cohorts with different selection criteria and study design. Furthermore, microvascular lesions seem to have a more significant effect on dementia in younger compared with older participants. The results from this study demonstrate that different populations may require distinct dementia interventions, underscoring the need for disease-specific biomarkers.
引用
- Cholerton B, Latimer CS, Crane PK, et al. Neuropathologic Burden and Dementia in Nonagenarians and Centenarians: Comparison of 2 Community-Based Cohorts. Neurology. 2024. PMID: 38175995. doi:10.1212/WNL.0000000000208060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。